Barr's conjugated estrogens ANDA
FDA Commissioner Young and other agency officials recently met with Sen. D'Amato (R-NY) to discuss Barr's ANDA application for conjugated estrogens. Reportedly, the senator asked whether Barr is being treated fairly in regard to the product's review and whether there has been any further action on the application. Pomona, New York-based Barr submitted blood level studies for the application in accordance with an FDA decision on bioequivalence requirements for generic forms of Ayerst's Premarin. FDA had earlier rejected Barr's urinary excretion-based ANDA for estrogens. In a recent letter to FDA, Sen. Hatch (R-Utah) also expressed interest in FDA's review of Barr's generic conjugated estrogens.
You may also be interested in...
The calcineurin inhibitor, only the second drug to be approved by the US FDA for lupus nephritis, will be competing against GlaxoSmithKline’s Benlysta.
Federal prosecutors’ latest criminal case alleging fraudulent advertising and sales of vitamins and other nutrients available nonprescription in the US as remedies for infections from the novel coronavirus is against Johnny Stine, owner and operator of North Coast Biologics in Seattle.
Executives expect the changes wrought by necessity in the face of a global pandemic to have lasting effects, both positive and negative, on the biopharma sector. Here they share their predictions for the coming year.